基本信息
浏览量:459
职业迁徙
个人简介
Special interests:
Prostate cancer
His clinical practice concerns the management of prostate cancer. Research interests include active surveillance of low-risk disease, post-operative adjuvant therapy, and radionuclide therapy for advanced disease. He is a former Chair of the National Cancer Research Institute Prostate Clinical Studies Group. He has published over 250 articles on prostate cancer.
Clinical units
Urology
Professor Parker led the clinical development of radium-223, a targeted alpha-emitter for the treatment of bone metastases. The ALSYMPCA trial demonstrated that radium-223 improves overall survival and quality of life in men with advanced prostate cancer and has a favourable safety profile.
He also led the Medical Research Council STAMPEDE RT/M1 comparison. The results showed that prostate radiotherapy improves overall survival in men with low burden metastatic disease.
He is a leading researcher for The London Movember Centre of Excellence.
Professor Parker is currently leading two phase III trials of post-operative treatment: The RADICALS-RT trial compares adjuvant versus salvage radiotherapy. The RADICALS-HD trial compares three different durations of androgen deprivation in men receiving post-operative radiotherapy. Together these trials recruited over 3000 patients and the results are due around 2020.
Prostate cancer
His clinical practice concerns the management of prostate cancer. Research interests include active surveillance of low-risk disease, post-operative adjuvant therapy, and radionuclide therapy for advanced disease. He is a former Chair of the National Cancer Research Institute Prostate Clinical Studies Group. He has published over 250 articles on prostate cancer.
Clinical units
Urology
Professor Parker led the clinical development of radium-223, a targeted alpha-emitter for the treatment of bone metastases. The ALSYMPCA trial demonstrated that radium-223 improves overall survival and quality of life in men with advanced prostate cancer and has a favourable safety profile.
He also led the Medical Research Council STAMPEDE RT/M1 comparison. The results showed that prostate radiotherapy improves overall survival in men with low burden metastatic disease.
He is a leading researcher for The London Movember Centre of Excellence.
Professor Parker is currently leading two phase III trials of post-operative treatment: The RADICALS-RT trial compares adjuvant versus salvage radiotherapy. The RADICALS-HD trial compares three different durations of androgen deprivation in men receiving post-operative radiotherapy. Together these trials recruited over 3000 patients and the results are due around 2020.
研究兴趣
论文共 427 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
European Radiologyno. 2 (2024): 1146-1154
Dr Rosalyne Laura Westley,Katie Biscombe,A. Dunlop,A. Mitchell,Uwe Oelfke, Simeon Nil,Julia Murray, A. Pathmanathan,S. Hafeez,Chris Parker,Ragu Ratnakumaran,S. Alexander,
引用0浏览0引用
0
0
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICSno. 3 (2023): 624-629
Chris Parker,Nina Tunariu, Holly Tovey,Roberto Alonzi, Matthew D. Blackledge,Gary J. R. Cook,Sue Chua,Yong Du,Shaista Hafeez,Iain Murray,Anwar R. Padhani,John Staffurth,
JNCI CANCER SPECTRUMno. 6 (2023)
Gerhardt Attard,Joost F. Swennenhuis,David Olmos,Alison H.M. Reid,Elaine Vickers, Roger A'Hern, Rianne Levink,Frank Coumans, Joana Moreira,Ruth Riisnaes,Nikhil Babu Oommen, George Hawche,
crossref(2023)
Alison C Tree,Laura Satchwell,Emma Alexander,Irena Blasiak-Wal,Nandita M deSouza,Annie Gao, Emily Greenlay,Helen McNair,Chris Parker, James Talbot,David Dearnaley,Julia Murray
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn